Advertisement
New Zealand markets close in 6 hours 24 minutes
  • NZX 50

    11,790.92
    -12.36 (-0.10%)
     
  • NZD/USD

    0.5935
    +0.0015 (+0.25%)
     
  • ALL ORDS

    7,937.90
    +35.90 (+0.45%)
     
  • OIL

    83.37
    +0.01 (+0.01%)
     
  • GOLD

    2,336.10
    -6.00 (-0.26%)
     

Why Heron Therapeutics Shares Rose Nearly 15% This Week

Why Heron Therapeutics Shares Rose Nearly 15% This Week

The company announced on Thursday that its drug Zynrelef (bupivacaine and meloxicam) has been given Food and Drug Administration supplemental New Drug Application approval for more uses. The drug, the first FDA-approved dual-acting anesthetic, had already been approved in May for post-surgical pain relief after the removal of bunions, open inguinal hernia operations, or total knee replacement in adults. It has shown to be more effective than just bupivacaine alone, the current standard of care for post-surgical pain, and it gives surgeons a non-opioid solution for post-surgical pain, reducing the possibility of addiction.